Abbott Laboratories (ABT) is a focal point of our May 29, 2026, healthcare sector coverage.
What the data shows
As of May 29, 2026, ABT trades at $86.30 against a consensus target of $118.64, implying 37.5% upside. With 25 analysts contributing to this outlook, the stock carries a "buy" consensus. Valuation metrics include a 23.97 P/E, a 14.23 forward P/E, and a 2.94% dividend yield. The beta sits at 0.647, reflecting lower volatility than the broader market. Recent target shifts include a downward adjustment from Piper Sandler to $115 and Barclays to $143, while BTIG holds at $131.
| Metric | Value |
|---|---|
| Price | $86.30 |
| Target | $118.64 |
| Upside | 37.5% |
| Analysts | 25 |
How to read these figures
Consensus targets represent the average of forward-looking estimates from financial institutions. The upside percentage is the difference between current price and the mean target. A "buy" label reflects the aggregate sentiment of the 25 analysts, not a personal directive. Note that price targets are snapshots; they do not predict future performance.
ABT in context
ABT currently ranks first in the healthcare sector for analyst-projected upside at 37.5%, significantly above the 16.1% sector average. Peers like DHR (36.4%) and TMO (25.5%) follow, though individual firm targets vary widely. Insider activity shows 4 meaningful buys versus 6 sells, though such data is historical and should not be used as a primary signal for future price movement. Explore more at ABT details.
Key takeaways
* ABT holds the top rank for projected upside within our healthcare sector tracking. * The stock trades at a forward P/E of 14.23 with a 2.94% dividend yield. * Analyst targets remain fluid, with recent revisions showing moderate downward adjustments.
Frequently asked questions
What does the consensus target mean?
It is the average price estimate provided by Wall Street firms, serving as a baseline for how analysts view the stock's future value.
Why does the upside percentage matter?
It indicates the variance between current market pricing and analyst expectations, helping to visualize the degree of divergence in professional opinion.